China Pharma Holdings (CPHI) EBIT Margin (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly EBIT Margin came in at 113.6% in Q1 2026, down 4683.0% YoY from 2.48% in Q1 2025, and down 16.04% on a QoQ basis from 97.9% in Q4 2025.
China Pharma Holdings (CPHI) EBIT Margin (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of EBIT Margin data on file, last reported at 113.6% in Q1 2026.
- Quarterly EBIT Margin fell 4683.0% year-over-year to 113.6% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 90.13% (up 1303.0% YoY) and the FY2025 annual result came in at 78.16%, up 2317.0% from the prior year.
- EBIT Margin retreated to 113.6% in Q1 2026, from 97.9% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 20.28% in Q1 2023 to a low of 150.44% in Q2 2024.
- A 5-year average of 69.59% and a median of 63.57% in 2025 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2024 — EBIT Margin sank 10888 bps — and 2025, when it jumped 8687 bps.
- Tracing CPHI's EBIT Margin over 5 years: stood at 40.02% in 2022, then tumbled by 38 bps to 55.1% in 2023, then sank by 91 bps to 105.47% in 2024, then grew by 7 bps to 97.9% in 2025, then decreased by 16 bps to 113.6% in 2026.
- The last three EBIT Margin figures came in at 113.6% (Q1 2026), 97.9% (Q4 2025), and 83.06% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | China Pharma Holdings | 42.70 Mn | 42.39 Mn | 83,566.00 | -150.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -113.60% |
| Dec 31, 2025 | -97.90% |
| Sep 30, 2025 | -83.06% |
| Jun 30, 2025 | -63.57% |
| Mar 31, 2025 | -66.76% |
| Dec 31, 2024 | -105.47% |
| Sep 30, 2024 | -98.65% |
| Jun 30, 2024 | -150.44% |
| Mar 31, 2024 | -66.87% |
| Dec 31, 2023 | -55.10% |
| Sep 30, 2023 | -39.57% |
| Jun 30, 2023 | -41.56% |
| Mar 31, 2023 | -20.28% |
| Dec 31, 2022 | -40.02% |
| Sep 30, 2022 | -35.03% |
| Jun 30, 2022 | -48.33% |
| Mar 31, 2022 | -56.84% |
| Dec 31, 2021 | -22.45% |
| Sep 30, 2021 | -38.53% |
| Jun 30, 2021 | -31.17% |